Monthly
US$200
Billed every month
Oxaliplatin Injection(奥沙利铂注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders6View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers21View records ↓
API companies with A status26View records ↓
Chemical-drug catalogue
Loaded records: 6 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 6 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| — | 吉斯美（武汉）制药有限公司 | 国药准字H20244951 | 2024/09/19 | 10ml：50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 健进制药有限公司 | 健进制药有限公司 | 国药准字H20244822 | 2024/09/03 | 10ml：50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 健进制药有限公司 | 健进制药有限公司 | 国药准字H20244821 | 2024/09/03 | 20ml：100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海创诺制药有限公司 | 上海创诺制药有限公司 | 国药准字H20244539 | 2024/07/30 | 10ml：50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20213540 | — | 10ml:50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20213541 | — | 20ml:100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川汇宇制药股份有限公司 | 四川汇宇制药股份有限公司 | 国药准字H20213061 | 2021/01/30 | 20ml:100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川汇宇制药股份有限公司 | 四川汇宇制药股份有限公司 | 国药准字H20213060 | 2021/01/30 | 10ml:50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 齐鲁制药(海南)有限公司 | 国药准字H20203217 | 2020/05/26 | 20ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 齐鲁制药(海南)有限公司 | 国药准字H20203216 | 2020/05/26 | 10ml:50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 齐鲁制药(海南)有限公司 | 国药准字H20203218 | 2020/05/26 | 40ml:0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 21 distinct approval numbers and 11 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 深圳海王药业有限公司 | 国药准字H20031048 | 20ml:40mg | Category B (乙) | XL01XAA215B002010100503 | NHSA |
| 上海创诺制药有限公司 | 国药准字H20244539 | 10ml:50mg | Category B (乙) | XL01XAA215B002010100647 | NHSA |
| 江苏恒瑞医药股份有限公司 | 国药准字H20213312 | 10ml:50mg | Category B (乙) | XL01XAA215B002010101445 | NHSA |
| 吉斯美(武汉)制药有限公司 | 国药准字H20244951 | 10ml:50mg | Category B (乙) | XL01XAA215B002010101892 | NHSA |
| 四川汇宇制药股份有限公司 | 国药准字H20213060 | 10ml:50mg | Category B (乙) | XL01XAA215B002010102317 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20213540 | 10ml:50mg | Category B (乙) | XL01XAA215B002010104188 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203216 | 10ml:50mg | Category B (乙) | XL01XAA215B002010105847 | NHSA |
| 湖北一半天制药有限公司 | 国药准字H20265985 | 10ml:50mg | Category B (乙) | XL01XAA215B002010106932 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20255932 | 20ml:100mg | Category B (乙) | XL01XAA215B002010109910 | NHSA |
| 健进制药有限公司 | 国药准字H20244821 | 20ml:100mg | Category B (乙) | XL01XAA215B002010181926 | NHSA |
| 贵州阜康仁制药有限公司 | 国药准字H20249605 | 10ml:50mg | Category B (乙) | XL01XAA215B002010183571 | NHSA |
| 深圳海王药业有限公司 | 国药准字H20031048 | 20ml:40mg | Category B (乙) | XL01XAA215B002010200503 | NHSA |
| 四川汇宇制药股份有限公司 | 国药准字H20213060 | 10ml:50mg | Category B (乙) | XL01XAA215B002010202317 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20213540 | 10ml:50mg | Category B (乙) | XL01XAA215B002010204188 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203216 | 10ml:50mg | Category B (乙) | XL01XAA215B002010205847 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20255932 | 20ml:100mg | Category B (乙) | XL01XAA215B002010209910 | NHSA |
| 江苏恒瑞医药股份有限公司 | 国药准字H20213313 | 20ml:100mg | Category B (乙) | XL01XAA215B002020101445 | NHSA |
| 四川汇宇制药股份有限公司 | 国药准字H20213061 | 20ml:100mg | Category B (乙) | XL01XAA215B002020102317 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20213541 | 20ml:100mg | Category B (乙) | XL01XAA215B002020104188 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203217 | 20ml:0.1g | Category B (乙) | XL01XAA215B002020105847 | NHSA |
| 湖北一半天制药有限公司 | 国药准字H20265986 | 20ml:100mg | Category B (乙) | XL01XAA215B002020106932 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20255933 | 10ml:50mg | Category B (乙) | XL01XAA215B002020109910 | NHSA |
| 健进制药有限公司 | 国药准字H20244822 | 10ml:50mg | Category B (乙) | XL01XAA215B002020181926 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20213541 | 20ml:100mg | Category B (乙) | XL01XAA215B002020204188 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20255933 | 10ml:50mg | Category B (乙) | XL01XAA215B002020209910 | NHSA |
| 湖北一半天制药有限公司 | 国药准字H20265987 | 40ml:200mg | Category B (乙) | XL01XAA215B002030106932 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20255931 | 40ml∶200mg | Category B (乙) | XL01XAA215B002030109910 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20203218 | 40ml:0.2g | Category B (乙) | XL01XAA215B002030205847 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 2 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 合肥力成药业有限公司 | CYHS2601692 | Generic | 2026/07/15 | Not stated by source | CDE |
| 合肥力成药业有限公司 | CYHS2601691 | Generic | 2026/07/15 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2602705 | Generic | 2026/11/05 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2602703 | Generic | 2026/11/05 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 合肥力成药业有限公司 | CYHS2601692 | Generic | 2026/07/15 | Not stated by source | CDE |
| 合肥力成药业有限公司 | CYHS2601691 | Generic | 2026/07/15 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2602705 | Generic | 2026/11/05 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2602703 | Generic | 2026/11/05 | Not stated by source | CDE |
API registrations
Non-component matches: 26 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 奥沙利铂 | 湖北一半天制药有限公司 | Y20210001223 | A | Exact ingredient | 2023/06/28 | CDE |
| 奥沙利铂 | HERAEUS PRECIOUS METALS GMBH & CO. KG | Y20210001055 | A | Exact ingredient | 2025/09/24 | CDE |
| 奥沙利铂 | Debiopharm International S.A. | Y20200001275 | I | Exact ingredient | 2021/01/15 | CDE |
| 奥沙利铂 | 昆明贵研药业有限公司 | Y20190009875 | A | Exact ingredient | 2023/12/06 | CDE |
| 奥沙利铂 | 江苏恒瑞医药股份有限公司 | Y20190009632 | A | Exact ingredient | 2025/08/22 | CDE |
| 奥沙利铂 | 齐鲁制药有限公司 | Y20190009353 | A | Exact ingredient | 2025/02/27 | CDE |
| 奥沙利铂 | 先声药业有限公司 | Y20190007591 | A | Exact ingredient | 2024/04/29 | CDE |
| 奥沙利铂 | 远大医药黄石飞云制药有限公司 | Y20190007556 | A | Exact ingredient | 2024/08/17 | CDE |
| 奥沙利铂 | 无锡紫杉药业股份有限公司 | Y20190007479 | A | Exact ingredient | 2025/07/30 | CDE |
| 奥沙利铂 | 浙江海正药业股份有限公司 | Y20190007430 | A | Exact ingredient | 2023/09/09 | CDE |
| 奥沙利铂 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20190007392 | A | Exact ingredient | 2023/10/13 | CDE |
| 奥沙利铂 | 山东罗欣药业集团恒欣药业有限公司 | Y20190006879 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 南京臣功制药股份有限公司 | Y20190006604 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 苏州立新制药有限公司 | Y20190006084 | A | Exact ingredient | 2026/02/25 | CDE |
| 奥沙利铂 | 重庆泰濠制药有限公司 | Y20190005513 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 成都长青制药有限公司 | Y20190004910 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 南京海润医药有限公司 | Y20190004758 | A | Exact ingredient | 2025/08/05 | CDE |
| 奥沙利铂 | 深圳海王药业有限公司 | Y20190004459 | A | Exact ingredient | 2024/12/25 | CDE |
| 奥沙利铂 | 南京制药厂有限公司 | Y20190004335 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 远大武药（江苏）制药有限公司 | Y20190001417 | A | Exact ingredient | 2025/06/29 | CDE |
| 奥沙利铂 | 费森尤斯卡比（武汉）医药有限公司 | Y20190001358 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 南京瑞年百思特制药有限公司 | Y20190001357 | A | Exact ingredient | — | CDE |
| 奥沙利铂 | 兰西哈三联制药有限公司 | Y20190001328 | A | Exact ingredient | 2024/06/06 | CDE |
| 奥沙利铂 | UMICORE ARGENTINA S.A. | Y20190000501 | A | Exact ingredient | 2026/01/05 | CDE |
| 奥沙利铂 | 齐鲁制药有限公司 | Y20180001626 | A | Exact ingredient | 2019/01/02 | CDE |
| 奥沙利铂 | 昆明贵研药业有限公司 | Y20180000346 | A | Exact ingredient | 2026/06/26 | CDE |
| 奥沙利铂 | 江苏恒瑞医药股份有限公司 | Y20170002037 | A | Exact ingredient | 2025/04/02 | CDE |
| 奥沙利铂 | 山东铂源药业股份有限公司 | Y20170000383 | A | Exact ingredient | 2024/04/16 | CDE |
| 奥沙利铂 | Heraeus Precious Metals GmbH & Co. KG | Y20170000338 | I | Exact ingredient | — | CDE |
| 奥沙利铂 | Fresenius Kabi Oncology Limited | Y20170000229 | I | Exact ingredient | — | CDE |
| 奥沙利铂 | 上海创诺制药有限公司 | Y20170000110 | A | Exact ingredient | 2023/03/24 | CDE |
| 奥沙利铂 | Shilpa Medicare LTD | Y20170000070 | A | Exact ingredient | 2024/07/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/05Accepted
-
2026/11/05Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Oxaliplatin Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy